1. Home
  2. LAC vs GLUE Comparison

LAC vs GLUE Comparison

Compare LAC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

HOLD

Current Price

$2.64

Market Cap

1.0B

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$11.67

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAC
GLUE
Founded
2023
2019
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
LAC
GLUE
Price
$2.64
$11.67
Analyst Decision
Hold
Strong Buy
Analyst Count
7
3
Target Price
$6.14
★ $32.00
AVG Volume (30 Days)
★ 8.9M
1.0M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $123,672,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.45
P/E Ratio
★ N/A
$72.42
Revenue Growth
N/A
★ 63.54
52 Week Low
$2.66
$7.24
52 Week High
$10.52
$25.77

Technical Indicators

Market Signals
Indicator
LAC
GLUE
Relative Strength Index (RSI) 34.84 28.53
Support Level N/A N/A
Resistance Level $3.31 $15.00
Average True Range (ATR) 0.11 0.62
MACD -0.02 0.01
Stochastic Oscillator 0.00 7.67

Price Performance

Historical Comparison
LAC
GLUE

About LAC Lithium Americas Corp.

Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Share on Social Networks: